DaVita HealthCare ( DVA ) Stock Slides as Market Rises: Facts to Know Before You Trade
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $128.14, denoting a -2.3% move from the preceding trading day.
DaVita HealthCare ( DVA ) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why DaVita HealthCare ( DVA ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DaVita HealthCare ( DVA ) Rises Higher Than Market: Key Facts
In the latest trading session, DaVita HealthCare (DVA) closed at $132.87, marking a +1.75% move from the previous day.
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Addus HomeCare and The Pennant
Quest Diagnostics, DaVita, Addus HomeCare, and The Pennant Group are positioned to benefit from telehealth, AI adoption, and rising demand in the $747B home healthcare market.
4 Outpatient Home Health Stocks Worth Watching Amid Shifting Trends
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, DVA, ADUS and PNTG are well-poised to gain.
VSee Health Secures Nasdaq Approval for Continued Listing
. ( Nasdaq: VSEE ) ( the "Company" ) , a provider of comprehensive telehealth services that customizes telehealth work-flow streams and enhances patient care, today announced that the Company was notified by The Nasdaq Stock Market LLC ( "Nasdaq" ) in a letter dated September 15, 2025, that the ...
DaVita HealthCare ( DVA ) Gains As Market Dips: What You Should Know
The latest trading day saw DaVita HealthCare (DVA) settling at $132.83, representing a +1.28% change from its previous close.
Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now
FMS acquisitions, partnerships and global reach fuel growth, though rising costs weigh on near-term prospects.
Warren Buffett Sold 6 Stocks in Q2. Here's Why 1 of Them Could Still Be a No-Brainer Buy.
Buying one stock Buffett recently sold could pay off nicely for long-term investors.
Sun Country Airlines Appoints Wendy Schoppert to Board of Directors
MINNEAPOLIS, Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- Sun Country Airlines ( NASDAQ: SNCY ) announced today the appointment of Twin Cities businessperson Wendy Schoppert to its Board of Directors, effective October 1, 2025.
Should Value Investors Buy DaVita ( DVA ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DaVita HealthCare ( DVA ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest trading session, DaVita HealthCare (DVA) closed at $128, marking a -1.62% move from the previous day.
Why DaVita HealthCare ( DVA ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DaVita HealthCare ( DVA ) Stock Drops Despite Market Gains: Important Facts to Note
DaVita HealthCare (DVA) closed at $132.26 in the latest trading session, marking a -3.26% move from the prior day.
Should Value Investors Buy DaVita ( DVA ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
What's Going With Dialysis Firm DaVita Stock On Friday? - DaVita ( NYSE:DVA )
Ransomware breach exposed 2.7 million DaVita patients' personal and health data. DaVita Q2 EPS of $2.95 beats $2.79 estimate; $2 billion share buyback approved. The market is reacting to Powell's speech. Learn how to time your next move. Details here →
2 Warren Buffett Stocks to Buy Hand Over Fist and 1 to Avoid
The Oracle of Omaha's investing strategies have stood the test of time.
Rockwell Medical RMTI Q2 2025 Earnings Transcript
Image source: The Motley Fool.Thursday, August 14, 2025 at 8 a.m. ETPresident and Chief Executive Officer - Mark StrobeckContinue reading ...
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Rockwell Medical Tops Q2 EPS View
Rockwell Medical ( NASDAQ:RMTI ) , a key supplier of hemodialysis concentrates, released its second quarter 2025 earnings on August 14, 2025. The most notable development was a steep year-over-year revenue decline of 38% as the company absorbed the financial impact of its largest customer's ...
Here's Why DaVita HealthCare ( DVA ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are Investors Undervaluing DaVita ( DVA ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 No-Brainer Warren Buffett Stocks to Buy Right Now
The Oracle of Omaha's approach to picking stocks still works as well as it ever has.
Akebia ( AKBA ) Q2 Revenue Jumps 43%
Akebia Therapeutics ( NASDAQ:AKBA ) , a biopharmaceutical company specializing in kidney disease treatments, reported its earnings on August 7, 2025, covering results for the quarter. The headline news was a marked upturn in revenue and a transition to positive GAAP net income.
DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands
DVA reports strong second-quarter 2025 results with earnings and revenue beat, along with a boost in gross margin, driven by core operations.
DaVita HealthCare ( DVA ) Q2 Earnings and Revenues Top Estimates
DaVita HealthCare (DVA) delivered earnings and revenue surprises of +9.26% and +1.31%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Warren Buffett Just Bought Even More of This Dirt-Cheap Stock
Berkshire Hathaway now owns 37% of this company.
Encompass Health ( EHC ) Q2 Earnings and Revenues Surpass Estimates
Encompass Health (EHC) delivered earnings and revenue surprises of +16.67% and +2.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Akebia Initiates Vafseo® ( vadadustat ) Post-Marketing Study in Conjunction with Large Dialysis Organization - Akebia Therapeutics ( NASDAQ:AKBA )
CAMBRIDGE, Mass., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc. AKBA, a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a post-marketing study to identify additional potential benefits of ...
DaVita HealthCare ( DVA ) Registers a Bigger Fall Than the Market: Important Facts to Note
DaVita HealthCare (DVA) closed the most recent trading day at $140.37, moving 2.91% from the previous trading session.
Can Phosphate Binders Drive DaVita Stock Before Q2 Earnings?
DVA rides early momentum from phosphate binders ahead of second-quarter 2025 earnings, but PD supply issues may cloud growth.
Vystar Introduces New RxAir-800 Replacement Cartridge Extended Life UV-C Bulb
New RxAir400 Pro UV-C bulb replacement cartridge provides 18,000 vs 9,000 hr. use.
Chemed ( CHE ) Q2 Earnings Miss Estimates
Chemed (CHE) delivered earnings and revenue surprises of -10.67% and +0.45%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
DaVita HealthCare ( DVA ) Reports Next Week: Wall Street Expects Earnings Growth
DaVita HealthCare (DVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Universal Health to Report Q2 Earnings: What Do the Key Estimates Say?
UHS' Q2 results are likely to reflect gains from hospital and behavioral health services. However, rising costs may cloud earnings upside.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Quest Diagnostics ( DGX ) Beats Q2 Earnings and Revenue Estimates
Quest Diagnostics (DGX) delivered earnings and revenue surprises of +1.95% and +1.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
DaVita HealthCare ( DVA ) Stock Sinks As Market Gains: What You Should Know
DaVita HealthCare (DVA) reached $139.43 at the closing of the latest trading day, reflecting a -1.23% change compared to its last close.
Will DaVita HealthCare ( DVA ) Beat Estimates Again in Its Next Earnings Report?
DaVita HealthCare (DVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
HCA Healthcare to Report Q2 Earnings: Key Estimates to Note
The Zacks Consensus Estimate for HCA's Q2 EPS and revenues suggests a year-over-year upside despite higher costs and surgery volume pressure.
DaVita HealthCare ( DVA ) Dips More Than Broader Market: What You Should Know
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $140.53, denoting a -2.01% move from the preceding trading day.
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
FMS continues to gain traction on the back of acquisitions & partnerships. A tough regulatory environment raises concerns.
Here's Why DaVita HealthCare ( DVA ) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DaVita HealthCare ( DVA ) Stock Sinks As Market Gains: Here's Why
DaVita HealthCare (DVA) concluded the recent trading session at $141.84, signifying a -1.36% move from its prior day's close.
Zacks Industry Outlook Highlights Quest Diagnostics, Encompass Health, DaVita and The Pennant
DGX, EHC, DVA, and PNTG are riding the outpatient healthcare shift as tech, AI, and aging demand reshape the care landscape.
